Non Alcoholic Steatohepatitis (NASH) Market

Non Alcoholic Steatohepatitis (NASH) Market - Global Industry Assessment & Forecast

Healthcare

# Pages:

169

Base Year:

2022

Jan - 2022

Format:

Report Code:

VMR-1253

Segments Covered

By Drug Type Vitamin E & Pioglitazone, Ocaliva, Elafibranor, Selonsertib, Cencicriviroc, Others
By Sales Channel Hospital Pharmacy, Online Provider, Retail Pharmacy
By Region North America, Latin America, Europe, Asia Pacific, Middle East & Africa

Standard License

$ 4299 USD

Multi User License

$ 6599 USD

Enterprise License

$ 6999 USD

Snapshot

Base Year:	2022
Forecast Years:	2023 - 2030
Historical Years:	2017 - 2021
Revenue 2022:	USD 2511.97 Million
Revenue 2030:	USD 108428.91 Million
Revenue CAGR (2023 - 2030):	60.10%
Fastest Growing Region (2023 - 2030)	Asia Pacific
Largest Region (2022):	North America

Customization Offered

Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market Dynamics
Region Level Market Share
Import Export Analysis
Production Analysis
Others Request Customization Speak To Analyst

Executive Dashboard
1. Strategic Imperatives
Premium Insights
1. Top 3 Trends to Watch
2. Demand and Supply Trends
3. Top 3 Strategies Followed by Major Players
4. Top 3 Predictions by Vantage Market Research
5. Top Investment Pockets
6. Insights from Primary Respondents
Global Non Alcoholic Steatohepatitis (NASH) Market - Segment Analysis
1. Overview
2. Global Non Alcoholic Steatohepatitis (NASH) Market, 2016 - 2028 (USD Million)
3. Global Non Alcoholic Steatohepatitis (NASH) Market - by Drug Type
  1. By Vitamin E & Pioglitazone
  2. By Ocaliva
  3. By Elafibranor
  4. By Selonsertib
  5. By Cencicriviroc
  6. By Others
4. Global Non Alcoholic Steatohepatitis (NASH) Market - by Sales Channel
  1. By Hospital Pharmacy
  2. By Online Provider
  3. By Retail Pharmacy
5. Global Non Alcoholic Steatohepatitis (NASH) Market - by region
  1. North America
  2. Europe
  3. Asia Pacific
  4. Latin America
  5. Middle East & Africa
6. Market comparative analysis
North America Non Alcoholic Steatohepatitis (NASH) Market - Segment Analysis
1. Overview
2. North America Non Alcoholic Steatohepatitis (NASH) Market, 2016 - 2028 (USD Million)
3. North America Non Alcoholic Steatohepatitis (NASH) Market, by Drug Type
  1. By Vitamin E & Pioglitazone
  2. By Ocaliva
  3. By Elafibranor
  4. By Selonsertib
  5. By Cencicriviroc
  6. By Others
4. North America Non Alcoholic Steatohepatitis (NASH) Market, by Sales Channel
  1. By Hospital Pharmacy
  2. By Online Provider
  3. By Retail Pharmacy
5. North America Non Alcoholic Steatohepatitis (NASH) Market, by Country
  1. U.S.
    1. U.S. Non Alcoholic Steatohepatitis (NASH) Market, By Drug Type
      1. By Vitamin E & Pioglitazone
      2. By Ocaliva
      3. By Elafibranor
      4. By Selonsertib
      5. By Cencicriviroc
      6. By Others
    2. U.S. Non Alcoholic Steatohepatitis (NASH) Market, By Sales Channel
      1. By Hospital Pharmacy
      2. By Online Provider
      3. By Retail Pharmacy
  2. Canada
    1. Canada Non Alcoholic Steatohepatitis (NASH) Market, By Drug Type
      1. By Vitamin E & Pioglitazone
      2. By Ocaliva
      3. By Elafibranor
      4. By Selonsertib
      5. By Cencicriviroc
      6. By Others
    2. Canada Non Alcoholic Steatohepatitis (NASH) Market, By Sales Channel
      1. By Hospital Pharmacy
      2. By Online Provider
      3. By Retail Pharmacy
  3. Mexico
    1. Mexico Non Alcoholic Steatohepatitis (NASH) Market, By Drug Type
      1. By Vitamin E & Pioglitazone
      2. By Ocaliva
      3. By Elafibranor
      4. By Selonsertib
      5. By Cencicriviroc
      6. By Others
    2. Mexico Non Alcoholic Steatohepatitis (NASH) Market, By Sales Channel
      1. By Hospital Pharmacy
      2. By Online Provider
      3. By Retail Pharmacy
Europe Non Alcoholic Steatohepatitis (NASH) Market - Segment Analysis
1. Overview
2. Europe Non Alcoholic Steatohepatitis (NASH) Market, 2016 - 2028 (USD Million)
3. Europe Non Alcoholic Steatohepatitis (NASH) Market, by Drug Type
  1. By Vitamin E & Pioglitazone
  2. By Ocaliva
  3. By Elafibranor
  4. By Selonsertib
  5. By Cencicriviroc
  6. By Others
4. Europe Non Alcoholic Steatohepatitis (NASH) Market, by Sales Channel
  1. By Hospital Pharmacy
  2. By Online Provider
  3. By Retail Pharmacy
5. Europe Non Alcoholic Steatohepatitis (NASH) Market, by Country
  1. Germany
    1. Germany Non Alcoholic Steatohepatitis (NASH) Market, By Drug Type
      1. By Vitamin E & Pioglitazone
      2. By Ocaliva
      3. By Elafibranor
      4. By Selonsertib
      5. By Cencicriviroc
      6. By Others
    2. Germany Non Alcoholic Steatohepatitis (NASH) Market, By Sales Channel
      1. By Hospital Pharmacy
      2. By Online Provider
      3. By Retail Pharmacy
  2. UK
    1. UK Market, By Drug Type
      1. By Vitamin E & Pioglitazone
      2. By Ocaliva
      3. By Elafibranor
      4. By Selonsertib
      5. By Cencicriviroc
      6. By Others
    2. UK Market, By Sales Channel
      1. By Hospital Pharmacy
      2. By Online Provider
      3. By Retail Pharmacy
  3. France
    1. France Non Alcoholic Steatohepatitis (NASH) Market, By Drug Type
      1. By Vitamin E & Pioglitazone
      2. By Ocaliva
      3. By Elafibranor
      4. By Selonsertib
      5. By Cencicriviroc
      6. By Others
    2. France Non Alcoholic Steatohepatitis (NASH) Market, By Sales Channel
      1. By Hospital Pharmacy
      2. By Online Provider
      3. By Retail Pharmacy
  4. Spain
    1. Spain Non Alcoholic Steatohepatitis (NASH) Market, By Drug Type
      1. By Vitamin E & Pioglitazone
      2. By Ocaliva
      3. By Elafibranor
      4. By Selonsertib
      5. By Cencicriviroc
      6. By Others
    2. Spain Non Alcoholic Steatohepatitis (NASH) Market, By Sales Channel
      1. By Hospital Pharmacy
      2. By Online Provider
      3. By Retail Pharmacy
  5. Italy
    1. Italy Non Alcoholic Steatohepatitis (NASH) Market, By Drug Type
      1. By Vitamin E & Pioglitazone
      2. By Ocaliva
      3. By Elafibranor
      4. By Selonsertib
      5. By Cencicriviroc
      6. By Others
    2. Italy Non Alcoholic Steatohepatitis (NASH) Market, By Sales Channel
      1. By Hospital Pharmacy
      2. By Online Provider
      3. By Retail Pharmacy
  6. BENELUX
    1. BENELUX Non Alcoholic Steatohepatitis (NASH) Market, By Drug Type
      1. By Vitamin E & Pioglitazone
      2. By Ocaliva
      3. By Elafibranor
      4. By Selonsertib
      5. By Cencicriviroc
      6. By Others
    2. BENELUX Non Alcoholic Steatohepatitis (NASH) Market, By Sales Channel
      1. By Hospital Pharmacy
      2. By Online Provider
      3. By Retail Pharmacy
  7. Rest of Europe
    1. Rest Of Europe Non Alcoholic Steatohepatitis (NASH) Market, By Drug Type
      1. By Vitamin E & Pioglitazone
      2. By Ocaliva
      3. By Elafibranor
      4. By Selonsertib
      5. By Cencicriviroc
      6. By Others
    2. Rest Of Europe Non Alcoholic Steatohepatitis (NASH) Market, By Sales Channel
      1. By Hospital Pharmacy
      2. By Online Provider
      3. By Retail Pharmacy
Asia Pacific Non Alcoholic Steatohepatitis (NASH) Market - Segment Analysis
1. Overview
2. Asia Pacific Non Alcoholic Steatohepatitis (NASH) Market, 2016 - 2028 (USD Million)
3. Asia Pacific Non Alcoholic Steatohepatitis (NASH) Market, by Drug Type
  1. By Vitamin E & Pioglitazone
  2. By Ocaliva
  3. By Elafibranor
  4. By Selonsertib
  5. By Cencicriviroc
  6. By Others
4. Asia Pacific Non Alcoholic Steatohepatitis (NASH) Market, by Sales Channel
  1. By Hospital Pharmacy
  2. By Online Provider
  3. By Retail Pharmacy
5. Asia Pacific Non Alcoholic Steatohepatitis (NASH) Market, by Country
  1. China
    1. China Non Alcoholic Steatohepatitis (NASH) Market, By Drug Type
      1. By Vitamin E & Pioglitazone
      2. By Ocaliva
      3. By Elafibranor
      4. By Selonsertib
      5. By Cencicriviroc
      6. By Others
    2. China Non Alcoholic Steatohepatitis (NASH) Market, By Sales Channel
      1. By Hospital Pharmacy
      2. By Online Provider
      3. By Retail Pharmacy
  2. Japan
    1. Japan Non Alcoholic Steatohepatitis (NASH) Market, By Drug Type
      1. By Vitamin E & Pioglitazone
      2. By Ocaliva
      3. By Elafibranor
      4. By Selonsertib
      5. By Cencicriviroc
      6. By Others
    2. Japan Non Alcoholic Steatohepatitis (NASH) Market, By Sales Channel
      1. By Hospital Pharmacy
      2. By Online Provider
      3. By Retail Pharmacy
  3. India
    1. India Non Alcoholic Steatohepatitis (NASH) Market, By Drug Type
      1. By Vitamin E & Pioglitazone
      2. By Ocaliva
      3. By Elafibranor
      4. By Selonsertib
      5. By Cencicriviroc
      6. By Others
    2. India Non Alcoholic Steatohepatitis (NASH) Market, By Sales Channel
      1. By Hospital Pharmacy
      2. By Online Provider
      3. By Retail Pharmacy
  4. South Korea
    1. South Korea Non Alcoholic Steatohepatitis (NASH) Market, By Drug Type
      1. By Vitamin E & Pioglitazone
      2. By Ocaliva
      3. By Elafibranor
      4. By Selonsertib
      5. By Cencicriviroc
      6. By Others
    2. South Korea Non Alcoholic Steatohepatitis (NASH) Market, By Sales Channel
      1. By Hospital Pharmacy
      2. By Online Provider
      3. By Retail Pharmacy
  5. South East Asia
    1. South East Asia Non Alcoholic Steatohepatitis (NASH) Market, By Drug Type
      1. By Vitamin E & Pioglitazone
      2. By Ocaliva
      3. By Elafibranor
      4. By Selonsertib
      5. By Cencicriviroc
      6. By Others
    2. South East Asia Non Alcoholic Steatohepatitis (NASH) Market, By Sales Channel
      1. By Hospital Pharmacy
      2. By Online Provider
      3. By Retail Pharmacy
  6. Rest of Asia Pacific
    1. Rest of Asia Pacific Non Alcoholic Steatohepatitis (NASH) Market, By Drug Type
      1. By Vitamin E & Pioglitazone
      2. By Ocaliva
      3. By Elafibranor
      4. By Selonsertib
      5. By Cencicriviroc
      6. By Others
    2. Rest of Asia Pacific Non Alcoholic Steatohepatitis (NASH) Market, By Sales Channel
      1. By Hospital Pharmacy
      2. By Online Provider
      3. By Retail Pharmacy
Latin America Non Alcoholic Steatohepatitis (NASH) Market - Segment Analysis
1. Overview
2. Latin America Non Alcoholic Steatohepatitis (NASH) Market, 2016 - 2028 (USD Million)
3. Latin America Non Alcoholic Steatohepatitis (NASH) Market, by Drug Type
  1. By Vitamin E & Pioglitazone
  2. By Ocaliva
  3. By Elafibranor
  4. By Selonsertib
  5. By Cencicriviroc
  6. By Others
4. Latin America Non Alcoholic Steatohepatitis (NASH) Market, by Sales Channel
  1. By Hospital Pharmacy
  2. By Online Provider
  3. By Retail Pharmacy
5. Latin America Non Alcoholic Steatohepatitis (NASH) Market, by Country
  1. Brazil
    1. Brazil Non Alcoholic Steatohepatitis (NASH) Market, By Drug Type
      1. By Vitamin E & Pioglitazone
      2. By Ocaliva
      3. By Elafibranor
      4. By Selonsertib
      5. By Cencicriviroc
      6. By Others
    2. Brazil Non Alcoholic Steatohepatitis (NASH) Market, By Sales Channel
      1. By Hospital Pharmacy
      2. By Online Provider
      3. By Retail Pharmacy
  2. Argentina
    1. Argentina Non Alcoholic Steatohepatitis (NASH) Market, By Drug Type
      1. By Vitamin E & Pioglitazone
      2. By Ocaliva
      3. By Elafibranor
      4. By Selonsertib
      5. By Cencicriviroc
      6. By Others
    2. Argentina Non Alcoholic Steatohepatitis (NASH) Market, By Sales Channel
      1. By Hospital Pharmacy
      2. By Online Provider
      3. By Retail Pharmacy
  3. Rest of Latin America
    1. Rest of Latin America Non Alcoholic Steatohepatitis (NASH) Market, By Drug Type
      1. By Vitamin E & Pioglitazone
      2. By Ocaliva
      3. By Elafibranor
      4. By Selonsertib
      5. By Cencicriviroc
      6. By Others
    2. Rest of Latin America Non Alcoholic Steatohepatitis (NASH) Market, By Sales Channel
      1. By Hospital Pharmacy
      2. By Online Provider
      3. By Retail Pharmacy
Middle East & Africa Non Alcoholic Steatohepatitis (NASH) Market - Segment Analysis
1. Overview
2. Middle East & Africa Non Alcoholic Steatohepatitis (NASH) Market, 2016 - 2028 (USD Million)
3. Middle East & Africa Non Alcoholic Steatohepatitis (NASH) Market, by Drug Type
  1. By Vitamin E & Pioglitazone
  2. By Ocaliva
  3. By Elafibranor
  4. By Selonsertib
  5. By Cencicriviroc
  6. By Others
4. Middle East & Africa Non Alcoholic Steatohepatitis (NASH) Market, by Sales Channel
  1. By Hospital Pharmacy
  2. By Online Provider
  3. By Retail Pharmacy
5. Middle East & Africa Non Alcoholic Steatohepatitis (NASH) Market, by Country
  1. GCC Countries
    1. GCC Countries Non Alcoholic Steatohepatitis (NASH) Market, By Drug Type
      1. By Vitamin E & Pioglitazone
      2. By Ocaliva
      3. By Elafibranor
      4. By Selonsertib
      5. By Cencicriviroc
      6. By Others
    2. GCC Countries Non Alcoholic Steatohepatitis (NASH) Market, By Sales Channel
      1. By Hospital Pharmacy
      2. By Online Provider
      3. By Retail Pharmacy
  2. South Africa
    1. South Africa Non Alcoholic Steatohepatitis (NASH) Market, By Drug Type
      1. By Vitamin E & Pioglitazone
      2. By Ocaliva
      3. By Elafibranor
      4. By Selonsertib
      5. By Cencicriviroc
      6. By Others
    2. South Africa Non Alcoholic Steatohepatitis (NASH) Market, By Sales Channel
      1. By Hospital Pharmacy
      2. By Online Provider
      3. By Retail Pharmacy
  3. Rest of Middle East & Africa
    1. Rest of Middle East & Africa Non Alcoholic Steatohepatitis (NASH) Market, By Drug Type
      1. By Vitamin E & Pioglitazone
      2. By Ocaliva
      3. By Elafibranor
      4. By Selonsertib
      5. By Cencicriviroc
      6. By Others
    2. Rest of Middle East & Africa Non Alcoholic Steatohepatitis (NASH) Market, By Sales Channel
      1. By Hospital Pharmacy
      2. By Online Provider
      3. By Retail Pharmacy
Key Market Dynamics
1. Introduction
2. Market Drivers
3. Market Restraints
4. Market Opportunities
5. Porter's Five Forces Analysis
6. PEST Analysis
7. Regulatory Landscape
8. Technology Landscape
9. Regional Market Trends
COVID 19 Impact Analysis
1. Key strategies undertaken by companies to tackle COVID-19
2. Short term dynamics
3. Long term dynamics
Marketing Stratagy Analysis
1. Marketing Channel
2. Direct Marketing
3. Indirect Marketing
4. Marketing Channel Development Trends
Competative Landscape
1. Competition Matrix - 2021
2. Company Market Share Analysis - 2021
3. Key Company Activities, 2018 - 2021
4. Strategic Developments - Heat Map Analysis
5. Company Offering Evaluation
6. Company Regional Presence Evaluation
Company Profiles
1. Genfit
2. Allergan plc (Tobira Therapeutics Inc.)
3. Bristol-Myers Squibb Company
4. Conatus Pharmaceuticals
5. Galectin Therapeutics Inc.
Key Primary Respondents - VERBATIM
Discussion Guide
Customization Offered
Annexure
List of Figures
List of Tables
List of Abbreviations

Vantage Market Research | 09-Feb-2022

Non Alcoholic Steatohepatitis (NASH) Market Projected to Reach USD 21,879 Million by 2028

FAQ

Frequently Asked Question

What is the global demand for Non Alcoholic Steatohepatitis (NASH) in terms of revenue?

The global Non Alcoholic Steatohepatitis (NASH) valued at USD 2511.97 Million in 2022 and is expected to reach USD 108428.91 Million in 2030 growing at a CAGR of 60.10%.

Which are the prominent players in the market?

The prominent players in the market are Genfit, Allergan plc (Tobira Therapeutics, Inc.), Bristol-Myers Squibb Company, Conatus Pharmaceuticals, Galectin Therapeutics, Inc..

At what CAGR is the market projected to grow within the forecast period?

The market is project to grow at a CAGR of 60.10% between 2023 and 2030.

What are the driving factors fueling the growth of the market.

The driving factors of the Non Alcoholic Steatohepatitis (NASH) include
- High Prevalence of Hypertension

Which region accounted for the largest share in the market?

North America was the leading regional segment of the Non Alcoholic Steatohepatitis (NASH) in 2022.

Non Alcoholic Steatohepatitis (NASH) Market

Non Alcoholic Steatohepatitis (NASH) Market - Global Industry Assessment & Forecast

Healthcare

Segments Covered

Snapshot

Customization Offered

FAQ

Frequently Asked Question

What is the global demand for Non Alcoholic Steatohepatitis (NASH) in terms of revenue?

Which are the prominent players in the market?

At what CAGR is the market projected to grow within the forecast period?

What are the driving factors fueling the growth of the market.

Which region accounted for the largest share in the market?

Vantage Market Research

Products & Services

Media

Contact Us

Non Alcoholic Steatohepatitis (NASH) Market

Non Alcoholic Steatohepatitis (NASH) Market - Global Industry Assessment & Forecast

Healthcare

Segments Covered

Snapshot

Customization Offered

FAQ

Frequently Asked Question

What is the global demand for Non Alcoholic Steatohepatitis (NASH) in terms of revenue?

Which are the prominent players in the market?

At what CAGR is the market projected to grow within the forecast period?

What are the driving factors fueling the growth of the market.

Which region accounted for the largest share in the market?

Related Reports

Request Sample Report for Non Alcoholic Steatohepatitis (NASH) Market

Vantage Point Interactive Dashboard